fluspirilene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1222 | 1841-19-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A long-acting injectable antipsychotic agent used for chronic schizophrenia.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.70 | mg | P |
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AG01 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Diphenylbutylpiperidine derivatives |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.57 | acidic |
| pKa2 | 8.44 | Basic |
| pKa3 | 3.93 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-1 adrenergic receptor | GPCR | Ki | 6.23 | PDSP | |||||
| Beta-2 adrenergic receptor | GPCR | Ki | 6.29 | PDSP | |||||
| D(2) dopamine receptor | GPCR | Ki | 9.44 | PDSP | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.24 | PDSP | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.64 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | ANTAGONIST | Ki | 7.20 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.82 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.93 | CHEMBL | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 7.32 | PDSP | |||||
| D(3) dopamine receptor | GPCR | Ki | 8.41 | PDSP | |||||
| Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 7.90 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.95 | PDSP | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | ANTAGONIST | Ki | 6 | IUPHAR | ||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.21 | PDSP | |||||
| D(4) dopamine receptor | GPCR | Ki | 8.06 | PDSP | |||||
| Glycine receptor subunit alpha-1 | Ion channel | EC50 | 5.92 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1E | GPCR | ANTAGONIST | Ki | 5.60 | IUPHAR | ||||
| Nociceptin receptor | GPCR | Ki | 6.30 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000167366 | NUI |
| D02629 | KEGG_DRUG |
| C0016383 | UMLSCUI |
| CHEBI:93369 | CHEBI |
| CHEMBL46516 | ChEMBL_ID |
| D005484 | MESH_DESCRIPTOR_UI |
| DB04842 | DRUGBANK_ID |
| 85 | IUPHAR_LIGAND_ID |
| 1801 | INN_ID |
| C5QA4GLR9M | UNII |
| 3396 | PUBCHEM_CID |
| 4507 | RXNORM |
| 003485 | NDDF |
| 321692003 | SNOMEDCT_US |
| 419373008 | SNOMEDCT_US |
Pharmaceutical products:
None